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Background: The neurotransmitter dopamine (DA) modulates executive functions, learning, and emotional
processing, all of which are impaired in individuals with autism spectrum disorders (ASDs). Our previous findings
suggest a role for dopamine-related genes in families with only affected males.
Methods: We examined two additional genes which affect DA function, the DRD2 and PPP1R1B (DARPP-32) genes,
in a cohort of 112 male-only affected sib-pair families. Selected polymorphisms spanning these genes were
genotyped and both family-based and population-based tests were carried out for association analysis. General
discriminant analysis was used to examine the gene-gene interactions in predicting autism susceptibility.
Results: There was a significantly increased frequency of the DRD2 rs1800498TT genotype (P= 0.007) in affected
males compared to the comparison group, apparently due to over-transmission of the T allele (P= 0.0003). The
frequency of the PPP1R1B rs1495099CC genotype in affected males was also higher than that in the comparison
group (P= 0.002) due to preferential transmission of the C allele from parents to affected children (P= 0.0009).
Alleles rs1800498T and rs1495099C were associated with more severe problems in social interaction (P= 0.0002 and
P= 0.0016, respectively) and communication (P= 0.0004 and P= 0.0046), and increased stereotypic behaviours
(P= 0.0021 and P= 0.00072). General discriminant analysis found that the DRD2 and PPP1R1B genes additively
predicted ASDs (P= 0.00011; Canonical R = 0.26) and explain ~7% of the variance in our families. All findings
remained significant following corrections for multiple testing.
Conclusion: Our findings support a role for the DRD2 and PPP1R1B genes in conferring risk for autism in families
with only affected males and show an additive effect of these genes towards prediction of affected status in our
families.
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Autism spectrum disorders (ASDs) are characterized by re-
petitive behaviours and interests, as well as deficiencies in
communication and social interaction. They are believed
to be complex, polygenic disorders predominantly charac-
terized by multifactorial inheritance [1], although Zhao
et al. [2] (2007) suggested that Mendelian inheritance may
apply to autism risk in a subgroup of families with affected
males. To address the significant genetic heterogeneity and
phenotypic variation seen among affected individuals,
which has confounded the conclusive identification of can-
didate genes for the majority of cases, we have been testing
genes for evidence of association with specific ASD endo-
phenotypes in an effort to identify a subgroup within the
ASD population whose members share an underlying
pathophysiology.
Abnormalities in neurotransmitter pathways can ac-
count for the deficits seen in persons with ASDs. In con-
trast to the attention which has been directed to the
study of genes involved in the glutamate [3], GABA [3]
and serotonin pathways [1], genes related to the synthe-
sis, function and metabolism of dopamine (DA) have
received little attention [4].
We have argued [5] that genes in the dopaminergic
(DAergic) pathway are excellent candidates based on
their affect on ASD behaviours. DA modulates motor
functions [6], cognitive processes (including executive
functions [7] and learning [8]), and emotional regulation
[9] - all of which are abnormal in individuals with autism
[10-13]. DA also plays a role in social interactions [14]
and the pathophysiology of stereotypies [15]; impair-
ments in social interaction and the presence of increased
stereotypies are core features of autism. Furthermore,
there is decreased DAergic activity in the medial pre-
frontal cortex (PFC) in children with autism [16], and
increased levels of the major metabolite of DA, homova-
nillic acid (HVA), in cerebrospinal fluid from affected
children compared to controls [17], indicating altered
DAergic function in these individuals.
Based on our earlier findings on the dopamine β-
hydroxylase (DBH) gene, which encodes the enzyme that
converts DA to norepinephrine, in mothers from male-
only affected sib-pair families [18], we have pursued a
comprehensive study of DA-related genes in mothers
and sons with ASDs. Since our initial study with DBH, in
which we found an increased frequency of the 19-bp de-
letion in mothers from male-only affected sib-pair fam-
ilies [18], we identified a 3-marker risk haplotype in the
dopamine D1 receptor (DRD1) gene [5] in our family co-
hort having only affected sons. Here we report our find-
ings on two other genes affecting DA levels and
function, the dopamine D2 receptor (DRD2) and protein
phosphatase 1, regulatory subunit 1B (PPP1R1B) genes,
and results of tests for gene-gene interactions.The DRD2 gene comprises eight exons [19] and maps
to 11q22-q23 [20]. It encodes the dopamine D2 receptor
which, in addition to its role in postsynaptic neurons,
acts as an autoreceptor mediating DA synthesis [21] and
neurotransmission [22] in DAergic neurons. The dopa-
mine D2 receptor is involved in the DAergic modulation
of executive functions [23], reversal learning [24] and
emotional processing [25]. Drd2−/− mice have abnormal
gait similar to that of individuals with Parkinson disease
[26], and the administration of antipsychotic medications
(e.g., risperidone, a dopamine D2 receptor antagonist)
has proven efficacious in treating symptoms associated
with ASDs [27].
The PPP1R1B gene, located at chromosome 17q12 and
comprising 7 exons (http://www.ncbi.nlm.nih.gov; Gen-
eID 84152), encodes DARPP-32, which is expressed in
dopaminoceptive (DAceptive) neurons [28] and mediates
the effects of both D1 and D2 dopamine receptor classes
[29]. For example, dopamine D2 receptor antagonist-
induced catalepsy in rats is attenuated in Ppp1r1b−/−
mice [30] and knockout mice are impaired in reversal
learning [31]. Genetic [32,33] and immunoblot [34] stud-
ies showed an association of PPP1R1B with altered PFC
DARPP-32 protein levels in schizophrenia and bipolar
disorder, two conditions for which DA dysfunction is evi-
dent and which exhibit comorbidity with autism [35].
There are two previous studies which examined the
DRD2 gene as a candidate gene for autism. The first [36]
reported an increased frequency of the TaqI A1 allele in
persons with autism (N= 33) compared to controls
(N= 314), whereas the second [37] found no evidence for
transmission disequilibrium of an intragenic microsatel-
lite in 39 affected sib-pair families. No association studies
have examined the role of PPP1R1B as a candidate gene
for ASDs.
Based on our hypothesis that DA-related genes are im-
portant in male-only affected sib-pair families [18], we
examined four markers at the DRD2 locus that are com-
monly used to investigate possible associations between
DAergic function and behavioural abnormalities [38],
and three polymorphisms at the PPP1R1B locus to deter-
mine whether there was an association of these DA-
related genes with autism.
Materials and methods
Subjects
The 112 affected sib-pair families and the comparison
group (N= 443) were previously described [5]. Briefly,
the study group included 28 families from Canada [18], 5
from the South Carolina Autism Project [39], and 79
families obtained through the Autism Genetic Resource
Exchange (AGRE) in the United States [40]. All families
have two or more children with either autism or an
ASD, including Asperger syndrome and pervasive
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approved by the Queen’s University Research Ethics
Board and written informed consent was obtained from
parents of all participating families from Canada and
South Carolina, and through AGRE [40].
All 443 samples from the comparison group (blood-
spots from anonymous newborns taken for the purpose
of PKU testing and made available from the Ontario
Ministry of Health) were available for the study of the
PPP1R1B locus. Two hundred and fifty-three comparison
group samples were used for the DRD2 gene studies.
There were no significant differences in the allele fre-
quencies for DRD2 (P= 0.57–0.93) and PPP1R1B
(P= 0.28–0.91) markers in males and females from the
respective comparison cohorts and thus our comparison
cohorts included both males and females. Although
comprehensive information regarding psychiatric and be-
havioural disorders is not available for the comparison
group, we do not expect the prevalence of ASDs in this
comparison group to be greater than that in the general
population, or approximately 1/110 [41].Marker amplification and genotyping
DRD2
Four polymorphisms (rs1799732 Ins/Del, rs1079597 G/
A, rs1800498 T/C and rs1800497 C/T) were studied at
the DRD2 locus (Figure 1). The DRD2 gene contains four
haplotype blocks [Haploview 4.1; available at http://hap-
map.ncbi.nlm.nih.gov] [42]. Three of the blocks are small
(<4 kb) and one block is 20 kb in size. One of four poly-
morphisms used in this study, rs1079597, is part of the
HapMap dataset. both this SNP and and rs1800498 are
located within the larger haplotype block and were







Figure 1 Illustration of the DRD2 locus. A schematic showing gene struc
rs1799732, rs1079597, rs1800498 and rs1800497 listing r2 of the comparison
Legend:▪ exon; intron; □ untranslated region.disorders. Primer sequences, PCR and digestion condi-
tions are shown in Table 1. All PCR reactions were car-
ried out using 5 ng of template DNA; digestion products
were separated on either 2% (rs1079597, rs1800498 and
rs1800497) or 2.5% (rs1799732) agarose gels and visua-
lized using ethidium bromide and UV illumination. In
order to minimize genotyping errors, DNAs from
affected individuals and family members were randomly
arranged on 96-well plates, and all results were inde-
pendently scored and tabulated by two persons.PPP1R1B
Three polymorphisms (rs1495099 G/C, rs907094 T/C
and rs3764352 A/G) were examined in the PPP1R1B
gene (Figure 2). These variants were chosen from the
NCBI dbSNP Build 121 database from the Human Gen-
ome Project (available at http://www.ncbi.nlm.nih.gov/
SNP/snp_summary.cgi) based on the following criteria:
the markers span the PPP1R1B locus, they have minor
allele frequencies (MAFs) of approximately 20%, and
alleles at rs907094 and rs3764352 are associated with
changes in DARPP-32 mRNA expression and measures
of cognitive performance [32]. The PPP1R1B locus has a
single haplotype block which includes rs907094 and
rs3764352 as haplotype-tagged SNPs (htSNPs). PCR
reactions were carried out using 5 ng of template DNA
and amplicons were digested using conditions shown in
Table 1. All digestion products were separated on 2%
agarose gels and visualized using ethidium bromide and
UV illumination. In order to minimize genotyping errors,
DNAs from affected individuals and family members
were randomly arranged on 96-well plates, and all results






ture, marker positions and measures of linkage disequilibrium between
group (N=244) followed by r2 of parents from families (N=213).
Table 1 PCR and digestion conditions for DRD2 and PPP1R1B markers used in this study
DRD2 Marker
(5′! 3′)1




rs1799732 Ins/Del F 5′-GAGAAGACTGGCGAGCAGAC-3′ 1.5 mM 63°C 35 BstNI (0.05)
R 5′-CCACCAAAGGAGCTGTACCT-3′
rs1079597 G/A3 F 5′-GATACCCACTTCAGGAAGTC-3′ 1.0 mM 55°C 34 TaqI (0.4)
R 5′-CAGTAAAGAACTAGGAGTCAG-3′
rs1800498 T/C3 F 5′-CCCAGCAGGGAGAGGGAGTA-3′ 1.0 mM 55°C 34 TaqI (0.4)
R 5′-GACAAGTACTTGGTAAGCATG-3′










rs1495099 G/C F 5′-TTGTTGCTGAGCTGAGATGC-3′ 1.0 mM 60°C 35 PvuII (0.3)
R 5′-CTCCAGGGAAATGCACAAAG-3′
rs907094 T/C F 5′-ACCTGATTGGGAGAGGGACT-3′ 1.0 mM 60°C 34 MseI (0.3)
R 5′-GTAAGCTGAGGGGCCTGTG-3′
rs3764352 A/G F 5′-CTGTTTTGGAGGGGTCTCAG-3′ 1.0 mM 60°C 35 BccI (0.3)
R 5′-TGGGAATACTGAAGAGTCAACC-3′
1Rs1799732 Ins/Del, rs1079597 G/A, rs1800498 T/C, and rs1800497 C/T previously known as −141 C Ins/Del, TaqI B, TaqI D, and TaqI A, respectively.
2Restriction enzymes obtained from New England Biolabs, Pickering, ON, Canada.
3Primer sequences have been reported previously [43].
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Prior to carrying out analyses, Mendelian errors were
checked in the family cohort using the FBAT program,
v1.5.5 [44]. DRD2 marker data on five families and
PPP1R1B marker data on two families were excluded
from the analyses due to identified Mendelian errors.
Single gene analyses were performed as previously
described [5]. To avoid allele and genotype frequency
distortion from using related individuals in case–control
comparisons, one affected individual was selected at ran-
dom from each family using SPSS v14.0 (SPSS, Chicago,





Figure 2 Illustration of the PPP1R1B locus. A schematic showing gene s
between rs1495099, rs907094 and rs3764352 listing r2 of the comparison g
Legend: ▪ exon; intron; □ untranslated region.used for single marker allele and genotype frequency
comparisons for all polymorphisms as well as general
discriminant analyses. Family-based association tests
(FBAT), including quantitative disequilibrium tests
(QTDT), were done using FBAT v1.5.5. Because FBAT
v1.5.5 can accommodate multiple affected individuals
from each family, all affected individuals including those
used for case–control comparisons, were included for
FBAT and QTDT analyses. The domains, ‘reciprocal so-
cial interaction’, ‘communication’ and ‘repetitive stereo-
typed behaviours’ used for QTDT analyses were derived




tructure, marker positions and measures of linkage disequilibrium
roup (N=435) followed by r2 of parents from families (N=216).
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Abnormalities in Communication’ (B1, B2(V), B3(V) and
B4) and ‘Restricted, Repetitive, and Stereotyped Patterns
of Behaviour’ (C1 to C4) subdomains in the ADI-R diag-
nostic algorithm [45].
General Discriminant Analysis (GDA) was used to
evaluate the predictive value of our single gene findings
in discriminating between individuals with and without
autism, as well as to test for evidence of interaction
effects between genes. Genotypes were coded as categor-
ical variables and GDA was performed using Statistica
9.1 [Statsoft, Tulsa, OK, USA].
Corrections for multiple comparisons
The contribution of a single gene to autism susceptibility
is predicted to be relatively small and thus difficult to de-
tect statistically. Although corrections for multiple test-
ing must be made in genetic association studies,
Bonferroni correction is thought to be too stringent, with
a high risk for rejecting true significant findings. The
false discovery rate (FDR) approach [46] is a compromise
between not correcting for multiple comparisons, which
is too lax, and Bonferroni adjustments, which are too
strict. FDR has two methods, the Benjamini and Hoch-
berg (BH) method and the Benjamini and Liu method
(BL) [46]. The BH method is appropriate for correcting
for both independent and positively-dependent compari-
sons [47], and thus is appropriate for genetic studies
using polymorphisms.
FDR corrections were performed separately for single
gene case–control and family-based comparisons, as well
as GDA findings, using an initial FDR threshold of 0.050.
Results
Linkage disequilibrium of polymorphisms at the DRD2
and PPP1R1B loci
High r2 measures of linkage disequilibrium (LD) were
observed between DRD2 polymorphisms rs1079597 and
rs1800497, with no LD between rs1799732 and
rs1079597 and rs1800497 (Figure 1). R-squared measures
between PPP1R1B markers showed high LD (r2> 0.9)
between rs907094 and rs3764352, and lower LD between
rs1495099 and rs907094 and rs3764352 (Figure 2).
Case–control comparisons
All four markers of DRD2 were in HWE in the compari-
son and family cohorts with the exception of rs1799732
and rs1800498 in affected males (P= 0.009 and P= 0.012,
respectively); all markers were in HWE in the parents
from these families. As shown in Table 2, there was an
increased frequency of the rs1800498 TT genotype
(P= 0.007) in affected males (43.4% versus 28.7% in the
comparison group), which remained significant following
FDR correction. No significant differences in genotypefrequencies of the other three markers were seen be-
tween cases and the comparison group (P= 0.32–0.51)
(Table 2). Separate analyses using the extended-transmis-
sion disequilibrium test (ETDT) showed that significant
over-transmission of the rs1800498 T allele was not from
mothers (21 transmitted, 11 untransmitted; χ2 = 3.125,
df = 1, P= 0.077) but was from fathers (26 transmitted,
12 untransmitted; χ2 = 5.158, df = 1, P= 0.023) to affected
sons. No differences in rs1800498 T allele or rs1800498
TT genotype frequencies were found between mothers
(P= 0.69 and P= 0.26, respectively) or fathers (P= 0.90
and P= 0.65, respectively) and the comparison group
(data not shown).
All three PPP1R1B markers were in HWE in the com-
parison group; none were in HWE in the cohort of
affected individuals (P= 0.008, P= 0.033 and P= 0.033,
respectively), although all markers were in HWE in the
parents (data not shown). As shown in Table 2, the
rs1495099 CC (P= 0.002), rs907094 CC (P= 0.028) and
rs3764352 GG (P= 0.025) genotype frequencies were
increased in affected males (22.0%, 14.5% and 14.5%, re-
spectively) relative to the comparison group (9.9%, 6.9%
and 6.7%, respectively). Findings on alleles of these poly-
morphisms were similar, with the minor allele frequen-
cies of all three markers, rs1495099 C, rs907094 C and
rs3764352 G, being increased in the affected males rela-
tive to the comparison group (P= 0.001, P= 0.014 and
P= 0.021, respectively, all remained significant following
FDR correction; data not shown).
Because we hypothesize that maternal effects including
genetic factors may contribute to autism susceptibility in
some autism families [18], we compared frequencies of
rs1495099 C alleles and rs1495099 CC genotypes be-
tween mothers (33.2% and 12.7%, respectively) and the
comparison group (28.7% and 9.9%, respectively) but
found no significant differences (P= 0.19 and P= 0.39, re-
spectively; data not shown).Family-based association tests
FBAT showed that the DRD2 rs1800498 T allele was
over-transmitted to affected males (P= 0.0003; significant
following FDR correction), while no evidence of prefer-
ential allele transmission was found for the other three
markers (P= 0.16–0.94) (Table 3). The rs1799732 Ins -
rs1079597 G - rs1800498 T - rs1800497 C (Ins-G-T-C)
haplotype, consisting of the major alleles for all four
markers, was over-transmitted to affected males but with
a P-value (P= 0.0009; data not shown) slightly higher
than that observed with rs1800498 T alone (P= 0.0003).
It should be noted that the additive model was used in
FBAT for polymorphisms at the DRD2 locus because of
the increased CT and TT genotype frequencies found for
rs1800498.




rs1799732 N Ins/Ins Del/Ins Del/Del χ2 (df = 2) P1
Comparison group 238 188 (79.0%) 46 (19.3%) 4 (1.7%)
Affected males3 109 89 (81.7%) 16 (14.7%) 4 (3.7%) 2.253 0.32 0.025
rs1079597 N G/G A/G A/A χ2 (df = 2) P
Comparison group 244 168 (68.9%) 71 (29.1%) 5 (2.0%)
Affected males3 105 70 (66.7%) 30 (28.6%) 5 (4.8%) 1.944 0.38 0.038
rs1800498 N T/T C/T C/C χ2 (df = 2) P
Comparison group 244 70 (28.7%) 130 (53.3%) 44 (18.0%)
Affected males3 106 46 (43.4%) 38 (35.8%) 22 (20.8%) 9.790 0.007 0.013
rs1800497 N C/C T/C T/T χ2 (df = 2) P
Comparison group 245 164 (66.9%) 69 (28.2%) 12 (4.9%)
Affected males3 107 65 (60.7%) 35 (32.7%) 7 (6.5%) 1.333 0.51 0.050
PPP1R1B Genotype FDR
threshold2
rs1495099 N C/C C/G G/G χ2 (df = 2) P1
Comparison group 434 43 (9.9%) 163 (37.6%) 228 (52.5%)
Affected males3 109 24 (22.0%) 39 (35.8%) 46 (42.2%) 12.273 0.002 0.0083
rs907094 N C/C C/T T/T χ2 (df = 2) P
Comparison group 434 30 (6.9%) 146 (33.6%) 258 (59.4%)
Affected males3 110 16 (14.5%) 38 (34.5%) 56 (50.9%) 7.176 0.028 0.033
rs3764352 N G/G A/G A/A χ2 (df = 2) P
Comparison group 434 29 (6.7%) 152 (35.0%) 253 (58.3%)
Affected males3 110 16 (14.5%) 38 (34.5%) 56 (50.9%) 7.408 0.025 0.025
1P-values less than 0.05 are in bold and P-values which remain significant following false-discovery rate (FDR) corrections for multiple comparisons are underlined.
2P-value≤ FDR threshold is significant.
3One affected individual was randomly chosen from each family.
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cause of the increased frequency of rs1495099 CC,
rs907094 CC and rs3764352 GG genotypes found in
affected individuals compared to the comparison cohort.
Family-based association analyses and FDR-based correc-
tions showed significant over-transmission of rs1495099
C (P= 0.00092) but not of rs907094 C (P= 0.11) or
rs3764352 G (P= 0.09) (Table 3). The rs1495099 C -
rs907094 C - rs3764352 G (C-C-G) haplotype was not
significantly over-transmitted to affected males
(P= 0.031; not significant following FDR correction; data
not shown) compared to that of rs1495099 C alone
(P= 0.00092).
Genotype-phenotype associations
We next used quantitative transmission disequilibrium
tests (QTDT) to determine whether the extent of impair-
ment in the core behaviours was more pronounced in
affected males with the risk allele. The DRD2 rs1800498
T allele was associated with more severe impairments inreciprocal social interaction (P= 0.0002), verbal commu-
nication (P= 0.0004), and repetitive and stereotyped
behaviours (P= 0.0021); these findings remained signifi-
cant following corrections for multiple comparisons.
The PPP1R1B rs1495099 C allele was associated with
higher ADI-R domain scores (more severe problems) in
affected males for social interaction (P= 0.0016), nonver-
bal communication (P= 0.0046), and stereotyped beha-
viours (P= 0.00072) (Table 4), with strong evidence for
association shown by multivariate QTDT between
rs1495099 C and the combined effect of all three ADI-R
subdomains (P= 0.00042; data not shown). All findings
were significant following FDR-based corrections.
General discriminant analyses
We used GDA to determine whether DA-related genes
predict ASD susceptibility in affected males compared to
the comparison group and to test for gene-gene interac-
tions. Tests were performed based on our single gene
findings for DRD2 and PPP1R1B from this study, and
Table 3 FBAT of marker allele transmissions under an additive model at the DRD2 locus and FBAT of marker allele
transmissions under a recessive model at the PPP1R1B locus in affected sib-pair families1
DRD2 # Observed Expected Z P2 FDR
Fam threshold3
rs1799732
Ins 31 90.0 84.0 1.4 0.16 0.030
Del 31 38.0 44.0 −1.4 0.16
rs1079597
G 56 149.0 148.0 0.17 0.86 0.040
A 56 71.0 72.0 −0.17 0.86
rs1800498
T 73 185.0 160.0 3.6 0.0003 0.010
C 73 115.0 140.0 −3.6 0.0003
rs1800497
C 63 171.0 170.5 0.08 0.94 0.050
T 63 89.0 89.5 −0.08 0.94
PPP1R1B #
Fam
Observed Expected Z P2 FDR
threshold3
rs1495099
G 52 42.0 43.8 −0.4 0.72 0.043
C 34 39.0 26.3 3.3 0.00092 0.0071
rs907094
T 52 46.0 48.3 −0.5 0.66 0.036
C 24 25.0 19.8 1.6 0.11 0.029
rs3764352
A 54 48.0 49.8 −0.3 0.73 0.050
G 26 27.0 21.3 1.7 0.09 0.021
1All affected individuals were included in the analyses.
2P-values less than 0.05 are in bold and P-values which remain significant following false-discovery rate (FDR) corrections for multiple comparisons are underlined.
3P-value≤ FDR threshold is significant.
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genotypes and PPP1R1B rs1495099 genotypes each sig-
nificantly contributed to prediction of ASDs in our fam-
ilies (P= 0.0063 and P= 0.00086, respectively), as well as
when weighted and tested together (P= 0.00011; Canon-
ical R = 0.26) (Table 5). We generated a classification
matrix to determine the percent correct classification of
individuals with and without autism based on DRD2
rs1800498 and PPP1R1B rs1495099 genotypes, and
found that 97% of individuals from our comparison co-
hort and 13% of individuals with autism were correctly
classified (the analysis was based on the a priori baseline
frequency of 70% of individuals without autism and 30%
of individuals with autism). Using the weighted scores to
predict group membership, we found that 72% of control
individuals and 64% of affected individuals were pre-
dicted correctly using DRD2 and PPP1R1B genotypes.
However, while ~7% of the variance was explained with
DRD2 rs1800498 and PPP1R1B rs1495099 genotypes,
addition of our previously identified DRD1 rs265981–rs4532–rs686 haplotypes to the analyses did not result in
a significant improvement in the overall canonical cor-
relation (Canonical R = 0.27).
Adding all possible two-way interactions between
DRD2 rs1800498 and PPP1R1B rs1495099 genotypes, as
well as comparisons between DRD1 rs265981–rs4532–
rs686 haplotypes and DRD2 rs1800498 genotypes, and
DRD1 rs265981–rs4532–rs686 haplotypes and PPP1R1B
rs1495099 genotypes, we found no evidence for gene-
gene interactions (P= 0.35–0.75; data not shown).
Discussion
Our model for the involvement of the DA pathway in de-
termining some of the core deficits of ASDs is based on
earlier results implicating the DBH gene as a maternal
effect locus, and on our hypothesis that autism suscepti-
bility is determined by a combination of fetal susceptibil-
ity genes and fetal gender as well as maternal effects
including maternal genetic factors [18]. Following our
findings with the DRD1 gene [5], and as part of our
Table 4 QTDT of rs1800498 alleles under an additive model at the DRD2 locus and QTDT of rs1495099 alleles under a
recessive model at the PPP1R1B locus in affected sib-pair families1
ADI-R
Subdomain
DRD2 # Observed Expected Z P2 FDR
rs1800498 Fam threshold3
Social T 56 2909.0 2452.5 3.7 0.0002 0.017
Interaction C 56 1557.0 2013.5 −3.7 0.0002
Verbal T 46 1364.0 1103.5 3.6 0.0004 0.033
Communication C 46 666.0 926.5 −3.6 0.0004
Stereotyped T 56 876.0 754.5 3.1 0.0021 0.050





Observed Expected Z P2 FDR
threshold3
Social C 19 480.0 283.5 3.2 0.0016 0.017
Interaction G 36 535.0 579.5 −0.5 0.59 0.042
Nonverbal C 10 108.0 52.3 2.8 0.0046 0.025
Communication G 20 130.0 123.3 0.2 0.82 0.050
Stereotyped C 19 142.0 79.8 3.4 0.00072 0.0083
Behaviours G 36 176.0 200.3 −0.9 0.38 0.033
1All affected males were included for QTDT analyses.
2P-values less than 0.05 are in bold and P-values which remain significant following false-discovery rate (FDR) corrections for multiple comparisons are underlined.
3P-value≤ FDR threshold is significant.
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genes are significant factors in the etiology of ASDs, we
found evidence for association of the DRD2 and
PPP1R1B genes with autism in affected males from mul-
tiple-incidence families.
We found an increased frequency of the DRD2
rs1800498 TT genotype (P= 0.007) in affected males
(43.4%) compared to the comparison group (28.7%)
(Table 2), and the rs1800498 T allele was over-transmit-
ted to affected children (P= 0.0003) (Table 3). The
rs1800498 risk allele was associated with more severe
impairments in social interaction (P= 0.0002), verbal
communication (P= 0.0004) and stereotyped behaviours
(P= 0.0021) in affected males (Table 4), and the
rs1800498 TT genotype was associated with an increased
risk for ASD with an OR of 1.9 [95% CI: 1.5–2.5]. In
addition, we examined three polymorphisms at the
PPP1R1B locus and identified the rs1495099 C allele as a
recessive risk allele for susceptibility to ASDs in male-
only affected sib-pair families. The CC genotype fre-
quency was increased in affected males (22.0%) relative
to the comparison group (9.9%, P= 0.002), and family-
based association tests using FBAT with a recessive
model showed distorted allele transmission with over-
transmission of this allele in families (P= 0.00092)
(Table 3). This allele was associated with greater impair-
ments in social interaction (P= 0.0016) and nonverbal
communication (P= 0.0046), and more severe stereo-
typed behaviours (P= 0.00072), core features of ASDs. Fi-
nally, the rs1495099 CC genotype was associated with anincreased risk for ASD with an OR of 2.6 [95% CI = 1.9–
3.6]. All findings were significant following FDR-based
corrections for multiple comparisons.
Functional effects of DRD2 and PPP1R1B risk alleles on
gene expression
Our findings at the DRD2 and PPP1R1B loci may reflect
the functional effects of unidentified risk variants in LD
with rs1800498 at DRD2 and rs1495099 at PPP1R1B.
Functional analyses of these markers have not been
reported but in silico analyses performed using PupaSuite
[available at http://pupasuite.bioinfo.cipf.es/] [48] did not
identify any putative functional role for these polymorph-
isms while analyses using FASTSNP [available at http://
fastsnp.ibms.sinica.edu.tw/pages/input_CandidateGen-
eSearch.jsp] [49] predicted a ‘very low-to-low’ effect for
rs1800498 at DRD2 as an intronic enhancer and a ‘very
low-to-medium’ effect for rs1495099 at PPP1R1B as a
regulatory region/intronic enhancer. Meyer-Lindenberg
et al. [32] (2007) identified a common 7-marker PPP1R1B
haplotype that was associated with increased DARPP-32
mRNA expression and improved performance on mea-
sures of working memory and cognitive flexibility. This
haplotype included the T and A alleles of rs907094 and
rs3764352 respectively, while a haplotype containing the
minor alleles at these loci (i.e. rs907094 C and rs3754352
G) was associated with decreased mRNA expression in
post-mortem brain. Houlihan et al. [50] (2009) screened
this 7-marker haplotype to test PPP1R1B as a genetic de-
terminant of cognitive ageing and found that rs907094 C
Table 5 General discriminant analysis of DRD2 rs1800498 and PPP1R1B rs1495099 genotypes towards prediction of
ASDs in affected males1
Eigenvalue Canonical Wilk’s χ2 df P3 FDR
R Lambda F2 threshold4
DRD2 - PPP1R1B 0.07 0.26 0.94 23.27 4 0.00011 0.017
DRD2 0.97 5.14 343 0.0063 0.050
PPP1R1B 0.96 7.20 343 0.00086 0.033
1One affected individual was randomly chosen from each family.
2Chi-statistic reported for additive test of DRD2 and PPP1R1B and F statistic reported for single gene tests.
3P-values less than 0.05 are in bold and P-values which remain significant following false-discovery rate (FDR) corrections for multiple comparisons are underlined.
4P-value≤ FDR threshold is significant.
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cognitive ability. However, our findings do not support an
association of either rs907094 C or rs3764352 G with aut-
ism in our family cohort. Unfortunately, because
rs1495099 was not included in these studies, its functional
role is not known. With respect to the DRD2 locus, the
rs1800498 polymorphism was found to be in low LD with
rs1799732, a functional variant in the DRD2 promoter
[51], in our comparison group and parents from families
(Figure 1). To investigate whether alleles from rs1799732
are contributing as a risk factor for autism susceptibility in
our families, comparisons between family-based tests of
rs1800498 and rs1799732 alleles considered separately
(P=0.0003 and P=0.16, respectively), and haplotypes con-
taining alleles from both rs1800498 and rs1799732,
showed that the observed over-transmission in families is
derived from rs1800498, and not because of the rs1799732
polymorphism (data not shown). However, only 31 families
were informative for rs1799732 compared to 73 families
for rs1800498, so we cannot determine from these findings
whether alleles from the functional variant rs1799732 are
contributing to autism susceptibility in our families. An-
other genetic variant at the DRD2 locus, rs1076560GT, has
been associated with altered mRNA isoform expression
[52,53] and differences in striatal post-synaptic D2 recep-
tor abundance [54]. Bertolini et al. [53] (2009) found in
control and schizophrenia cohorts (N=114 and N=91, re-
spectively) that individuals heterozygous for the minor “T”
allele perform worse in the N-back test of working mem-
ory but only at a high level of difficulty (2-back) compared
to individuals homozygous for the major “G” allele while
Zhang et al. [52] (2007) found using healthy subjects
(N=117) that heterozygous individuals performed worse
at higher attentional loads in the variable attentional con-
trol (VAC) task, and had increased activity as measured
using BOLD fMRI in PFC and striatum compared to indi-
viduals homozygous for the major allele. However, the true
contribution of this variant to DAergic function and cogni-
tion is unclear as no genotype effects of this polymorphism
to overall working memory performance and fMRI activity
were also reported [52,54]. Nevertheless, both rs1076560
and rs1079597 are in high LD in the HapMap CEU panel(r2> 0.9) and are found in the same 20 kb haplotype block
as rs1800498. However, no information is available regard-
ing LD between rs1076560 and rs1800498. It is of interest
that low LD (r2< 0.3) was found between rs1800498 and
rs1079597 in our comparison group and parents from
families (Figure 1). Additional families informative at these
DRD2 loci are needed to determine whether these func-
tional variants or another functional polymorphism in LD
with rs1800498 is responsible for the increased risk for
autism. In addition, functional analyses and resequencing
of both genes in affected individuals with this risk haplo-
type at DRD2 or the risk allele at PPP1R1B are required.
Pathophysiological contributions of DRD2 and PPP1R1B to
risk for autism
The QTDT results support an association of the DRD2
and PPP1R1B loci with autism (Table 4). A role for the
DRD2 gene in autism susceptibility is suggested by the
fact that antipsychotic medications, which prevent dopa-
mine D2 receptor activation, improve the core symptoms
of ASDs [55]. Postsynaptic D2 receptors and presynaptic
D2 autoreceptors are involved in the DAergic modula-
tion of cognitive and emotional processes that are
impaired in individuals with autism [56,57]. Thus, func-
tional polymorphisms which affect receptor availability
(e.g. altered gene expression), either postsynaptically on
DAceptive neurons or presynaptically on DAergic neu-
rons, may contribute to the impairments found in indivi-
duals with autism.
DARPP-32 mediates the downstream effects of dopa-
mine receptor activation, and thus plays an important
role in the modulation of DA-related processes which
are abnormal in individuals with autism. Unlike dopa-
mine receptors, which can be studied using systemic or
local administration of ligands, DARPP-32 is found in
the cytoplasm of DAceptive neurons and there are few
studies which have examined its role in DA-modulated
processes and behaviours. One such study by Hotte et al.
[58] (2006) found that administration of D1 receptor
antagonists in mice caused deficits in working memory
which coincided with decreased levels of phosphory-
lated-DARPP-32 in the PFC. Deficiencies in working
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are found in individuals with autism. Both Drd2 −/−
mice and Ppp1r1b −/− mice exhibit impairments in re-
versal learning compared to wild-type mice [31,60].
The role of DARPP-32 in mediating the DA-related
changes to neuronal excitability necessary for memory and
learning was shown in a study by Calabresi et al. [61]
(2000). These authors were unable to induce long-term po-
tentiation (LTP) and long-term depression (LTD), two
forms of synaptic plasticity, in the striatum of Ppp1r1b −/−
mice. DA has a role in synaptic plasticity in both the stri-
atum [62] and amygdala [63], subcortical structures that
are important for regulating emotional behaviours [64] and
social interactions [65], and are implicated in the patho-
physiology of repetitive behaviours [66].
Effects between dopamine-related genes and risk for ASD
Based on our findings in this study and our previous
findings [5], single-gene analyses showed evidence for
association of DRD1, DRD2 and PPP1R1B with autism in
male-only affected sib-pair families. We performed gen-
eral discriminant analysis using Statistica v9.1 to predict
ASD susceptibility in affected males, and to test for
evidence of gene-gene interactions of DA-related genes
and ASDs. We found that DRD2 rs1800498 genotypes
and PPP1R1B rs1495099 genotypes significantly contrib-
uted to prediction of ASDs in our families when tested
separately and together (P= 0.0063–0.00011), which
accounted for ~7% of the variance. These results were
significant following corrections for multiple compari-
sons (Table 5). We also found that 97% of individuals
from our comparison cohort and 13% of individuals with
autism were correctly classified while 72% of control
individuals and 64% of affected individuals were pre-
dicted correctly using a weighted additive combination
of DRD2 and PPP1R1B genotypes. The inclusion of
DRD1 rs265981–rs4532–rs686 haplotypes into the ana-
lysis did not significantly change our findings (data not
shown), and we found no evidence for gene-gene inter-
actions (data not shown).
Our findings suggest that single genes individually con-
fer risk of autism susceptibility in our families and, al-
though there was no evidence for gene-gene interactions
between DA-related genes and autism susceptibility per
se, we did find evidence that DRD2 and PPP1R1B to-
gether significantly contribute to ASD prediction. Thus,
while both genes independently confer risk of autism
susceptibility, there is a cumulative effect towards pre-
dicting whether an individual has the condition. Further-
more, based on our findings from GDA analysis we
found an effect size of ~7%. While this effect size is
small, it is comparable to those reported in similar stud-
ies [4]. These generally small effect sizes likely reflect the
highly heterogeneous nature of ASDs.Parent-of-origin effects of DRD1 and DRD2 alleles on
development
The increased transmission of the DRD1 rs265981 C
–rs4532 A –rs686 T (C-A-T) haplotype from mothers
(P= 0.029) [5], and of the DRD2 rs1800498 T allele from
fathers (P= 0.023), to affected sons suggests that imprint-
ing effects of these genes are also important risk factors
for ASDs. A role for imprinting has been proposed for
several brain-related disorders, including autism [67].
There is evidence of imprinting of genes from neuro-
transmitter pathways implicated in ASDs such as the 5-
hydroxytryptamine receptor 2A (HTR2A) gene in the
serotoninergic pathway [68].
The dopamine D1 and D2 receptors are expressed in
human placentae [69,70] and fetal brains [71,72]. Placental
D1 and D2 receptors are involved in DA-mediated release
of opioids [73] and lactogen [74] respectively, which are
required for fetal development and growth . Both dopamine
D1 and D2 receptors are involved in brain development.
Dopamine D2 receptors expressed in fetal brain induce
neurite outgrowth and axon elongation while dopamine D1
receptors inhibit neurite outgrowth in cortical neuron dif-
ferentiation [75], with the opposite effects found in striatal
neuron differentiation [76]. There is no evidence for the
kind of parent-of-origin-specific DNA methylation at the
DRD1 or DRD2 loci in either human placentae or fetal
brains that is suggestive of imprinting [77]. Further, a review
of the ‘imprinted gene and parent-of-origin effect’ database
[available at http://igc.otago.ac.nz/home.html] [78] did not
yield any evidence supporting imprinting at either locus.
The possibility remains, however, that imprinting of these
genes may occur during a very narrow developmental
period or in a specific subpopulation of brain cells, as has
been demonstrated for the Ube3a gene in mice [79]. It
should be noted that the evidence presented for parent-of-
origin effects in ASDs is based on three markers in the
DRD1 gene and one marker in the DRD2 gene and thus,
more polymorphisms need to be studied to confirm our
findings.
Conclusions
Our results strongly support a role for the DRD2 and
PPP1R1B genes in susceptibility to autism spectrum beha-
viours in males from affected sib-pair families in which
there are only affected males, and especially those males
where there are severe impairments in social interaction
(DRD2 and PPP1R1B), verbal communication (DRD2),
nonverbal communication (PPP1R1B) and stereotyped
behaviours (DRD2 and PPP1R1B). Our results also support
an additive effect of the DRD2 and PPP1R1B genes in pre-
dicting ASDs in our families. However, we recognize that
large genome-wide association studies have not implicated
these genes in autism susceptibility, but those studies did
not analyse male-only affected sib-pair families separately
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level of impairments in the core characteristics of ASDs.
Further studies are needed using additional similar family
cohorts and sequencing of the DRD2 and PPP1R1B genes
in individuals with the risk alleles to identify functional
polymorphisms that could be associated with the clinical
findings in order to further develop our model for an asso-
ciation of DA-related gene function and susceptibility to
ASD behaviours.
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